SEC Form 4 · accession 0001493152-18-013540
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Brian McCartney
Officer — Chief Commercial Officer
Period of report
Aug 15, 2018
Accepted (ET)
Sep 20, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.03 | Aug 15, 2018 | A | 100,000 | A | — | Aug 15, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option award was made in accordance with the terms of the Amended and Restated Cancer Genetics, Inc. 2011 Equity Incentive Plan (the "2011 Plan"). The shares underlying the options shall become vested and exercisable with respect to twenty percent (20%) of the shares on the one-year anniversary of the date of grant and with respect to the remaining eighty percent (80%) of the shares in equal monthly installments on the 15th day of each of the forty-eight (48) calendar months thereafter, provided that the optionee remains a services provider to the Company through each applicable vesting period. The exercise price is the closing price of a share of Common Stock as of the date of grant on the NASDAQ Capital Market in accordance with the terms of the 2011 Plan.